<DOC>
	<DOCNO>NCT01392924</DOCNO>
	<brief_summary>Primary Objective : - To confirm safety tolerability global recommend phase three dose ( RPTD ) SAR245408 tablet administer continuous daily dosing ( CDD ) patient solid tumor . Secondary Objectives : - To evaluate plasma pharmacokinetics ( PK ) daily oral administration SAR245408 CDD treatment schedule patient solid tumor . - To gather preliminary efficacy data repeat administration SAR245408 patient solid tumor .</brief_summary>
	<brief_title>Safety Pharmacokinetics SAR245408 Daily Oral Patients With Solid Tumors</brief_title>
	<detailed_description>The duration study 1 patient include period screen 28 day , study treatment period , follow 28-day follow-up last study drug administration .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Histologically cytologically confirm solid tumor metastatic unresectable , standard curative palliative measure exist longer effective , know therapy prolong survival . Before studyspecific procedure , appropriate Institutional Review Board ( IRB ) approve write informed consent must obtain . Second informed consent must obtain patient start Treatment Extension Period ( Cycle 2 ) . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Exclusion criterion : &lt; 20 year old . Eastern Cooperative Oncology Group ( ECOG ) performance status &gt; 2 . Incapable understand comply protocol sign informed consent document . Unable unwilling abide study protocol cooperate fully investigator designee . Inadequate organ bone marrow function . Prothrombin time ( PT ) /International Normalized Ratio ( INR ) and/or partial thromboplastin time ( PTT ) test result screen 1.3 × laboratory upper limit normal ( ULN ) . Baseline correct QT interval ( QTc ) &gt; 460 ms. Sexually active ( male female ) agree use medically acceptable method contraception course study 3 month follow discontinuation study drug . Female patient childbearing potential must negative pregnancy test screening . Pregnant breastfeeding . Has tolerate previous treatment phosphatidylinositol 3kinase ( PI3K ) inhibitor , treat SAR245408 . Not recover previous therapy ( i.e . radiation , surgery , medication ) Currently receive anticoagulation therapeutic dos warfarin ( lowdose warfarin ≤ 1mg/day permit ) . Primary brain tumor brain metastasis consider eligible patient receive radiation therapy brain metastasis within 2 week enrollment stable dose steroid 2 week . Uncontrolled intercurrent illness include , limited , ongoing active infection ( include cytomegalovirus , EpsteinBarr virus , toxoplasmosis , hepatitis B C ) , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . Known positive human immunodeficiency virus ( HIV ) Psychiatric illness/social situation ( ) would limit compliance study requirement . Allergy hypersensitivity component SAR245408 formulation . Withdraws consent screening ( start sign informed consent form ( ICF ) ) Patient judge investigator suitable participate study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>